1,331 reports of this reaction
1.9% of all DONEPEZIL HYDROCHLORIDE reports
#11 most reported adverse reaction
SOMNOLENCE is the #11 most commonly reported adverse reaction for DONEPEZIL HYDROCHLORIDE, manufactured by Camber Pharmaceuticals, Inc.. There are 1,331 FDA adverse event reports linking DONEPEZIL HYDROCHLORIDE to SOMNOLENCE. This represents approximately 1.9% of all 69,498 adverse event reports for this drug.
Patients taking DONEPEZIL HYDROCHLORIDE who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is a less commonly reported adverse event for DONEPEZIL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to somnolence, the following adverse reactions have been reported for DONEPEZIL HYDROCHLORIDE:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 1,331 FDA reports for DONEPEZIL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 1.9% of all adverse event reports for DONEPEZIL HYDROCHLORIDE, making it a notable side effect.
If you experience somnolence while taking DONEPEZIL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.